ALPHA (drug)

ALPHA
Clinical data
Other names3,4-Methylenedioxy-α-ethylbenzylamine; 1-Amino-1-(3,4-methylenedioxyphenyl)propane
Routes of
administration		Oral
Drug classUnknown
ATC code
  • None
Pharmacokinetic data
Duration of action~3 hours
Identifiers
  • 1-(1,3-Benzodioxol-5-yl)propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13NO2
Molar mass179.219 g·mol−1
3D model (JSmol)
  • CCC(N)c1ccc2OCOc2c1
  • InChI=1S/C10H13NO2/c1-2-8(11)7-3-4-9-10(5-7)13-6-12-9/h3-5,8H,2,6,11H2,1H3 checkY
  • Key:VEOUOCLRLNJOLJ-UHFFFAOYSA-N checkY
  (verify)

ALPHA, also known as 3,4-methylenedioxy-α-ethylbenzylamine, is a psychoactive drug of the substituted benzylamine group and a positional isomer of 3,4-methylenedioxyamphetamine (MDA). It is also a benzylamine analogue of 3,4-methylenedioxyamphetamine (MDA). ALPHA was first synthesized by Alexander Shulgin. In his book PIHKAL on the MDA page, the threshold dosage is listed as 10 mg. At mild threshold dosages (around 10 mg) there are eyes-closed "dreams" with some body tingling, at higher doses (up to 140 mg) was reported to produce a pleasant, positive feeling. This compound is not anoretic at any dose. Its duration is about 3 hours. Very little data exists about the pharmacological properties, metabolism, and toxicity of ALPHA. The drug was encountered as a novel designer drug by 1996.

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 MDA Entry in PIHKAL
  2. 1 2 3 4 Shulgin A, Manning T, Daley PF (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
  3. ↑ King L, Poortman-van der Meer A, Huizer H (1996). "1-Phenylethylamines: a new series of illicit drugs?". Forensic Science International. 77 (3): 141–149. doi:10.1016/0379-0738(95)01852-2. PMID 8819989. Retrieved 9 April 2025.
  4. ↑ King LA (1996). "Designer drugs related to amphetamine (1990-1996)". Journal of the Clandestine Laboratory Investigating Chemists Association. 6 (3): 15–16.